Literature DB >> 19213850

Cancer preceding Wegener's granulomatosis: a case-control study.

Mikkel Faurschou1, Lene Mellemkjaer, Inge J Sorensen, Bjarne S Thomsen, Lene Dreyer, Bo Baslund.   

Abstract

OBJECTIVE: To investigate whether patients with WG have an increased risk of malignancies prior to and/or around the time of the vasculitis diagnosis, as suggested by previous studies.
METHODS: A total of 293 WG patients were included in the study. Ten gender- and age-matched controls were selected randomly for each patient from the Danish Central Population Register. Information on malignancies was obtained through the Danish Cancer Registry. Occurrence of malignancies before WG diagnosis among patients and before WG diagnosis of their matched case among controls (reference date) was compared by calculation of prevalence odds ratios (OR).
RESULTS: Twenty-six patients were diagnosed with cancer before WG, while 194 controls were diagnosed with cancer before the reference date (OR 1.4; 95% CI 0.9, 2.2). Among specific malignancies, a significantly increased prevalence was found for testis cancer (OR 6.4; 95% CI 1.1, 38) based on two patients, who developed testis cancer >10 years before WG. The overall prevalence of malignancies diagnosed <2 years before WG was not significantly increased (OR: 1.6; 95% CI: 0.8, 3.4), but non-melanoma skin cancer occurred with an increased prevalence within this time interval (OR 4.0; 95% CI 1.4, 12).
CONCLUSIONS: We did not find clear evidence of an increased prevalence of preceding cancer in our WG cohort, indicating that shared risk factors are of minor importance for the excess of malignancies that occur in WG patients after the vasculitis diagnosis. Furthermore, our current and previously reported latency analyses do not substantiate that serious malignancies play a significant role in the pathogenic events that trigger development of WG.

Entities:  

Mesh:

Year:  2009        PMID: 19213850     DOI: 10.1093/rheumatology/kep009

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  6 in total

Review 1.  Complications of long-term therapy for ANCA-associated systemic vasculitis.

Authors:  Nadezhda Wall; Lorraine Harper
Journal:  Nat Rev Nephrol       Date:  2012-06-05       Impact factor: 28.314

Review 2.  Key advances in the clinical approach to ANCA-associated vasculitis.

Authors:  Cees G M Kallenberg
Journal:  Nat Rev Rheumatol       Date:  2014-07-01       Impact factor: 20.543

3.  [Managing comorbidities of inflammatory rheumatic diseases].

Authors:  K de Groot; E Märker-Hermann
Journal:  Internist (Berl)       Date:  2011-06       Impact factor: 0.743

4.  Cancer preceding giant cell arteritis: a case-control study.

Authors:  Tanaz A Kermani; Valentin S Schäfer; Cynthia S Crowson; Gene G Hunder; Steven R Ytterberg; Eric L Matteson; Sherine E Gabriel; Kenneth J Warrington
Journal:  Arthritis Rheum       Date:  2010-06

5.  Beneficial Effect of Rituximab in the Treatment of Esophageal Cancer-Associated Pauci-Immune Glomerulonephritis.

Authors:  Heleen Ameye; Sabine Fransis; Evelyne Lerut; Christoph Metalidis; Ben Sprangers
Journal:  Kidney Int Rep       Date:  2016-06-29

6.  Cancer in Anti-Neutrophil Cytoplasm Antibody-Associated Vasculitis and Polyarteritis Nodosa in Australia: A Population-Based Study.

Authors:  Joanna Tieu; Susan Lester; Warren Raymond; Helen Keen; Catherine L Hill; Johannes Nossent
Journal:  ACR Open Rheumatol       Date:  2021-12-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.